ステージIV扁平上皮非小細胞肺癌（NSCLC）の一次治療におけるネシツムマブの研究

基本情報

NCT ID: NCT01763788
ステータス: 完了
試験のフェーズ: 第1/第2相
試験タイプ: 介入
目標被験者数: 192
治験依頼者名: Eli Lilly and Company

概要

The purpose of the Phase 1b portion of the study is to investigate how the body tolerates necitumumab, in combination with gemcitabine and cisplatin chemotherapy as first line treatment in participants with Stage IV squamous NSCLC and to determine the recommended dose for the subsequent Phase 2 portion of the study. The purpose of the Phase 2 portion of the study is to evaluate the efficacy of necitumumab in combination with gemcitabine and cisplatin chemotherapy in participants with Stage IV squamous NSCLC in a first-line setting.

対象疾患

Squamous Non-small Cell Lung Cancer

介入

Necitumumab(DRUG)

Gemcitabine(DRUG)

Cisplatin(DRUG)

依頼者（Sponsor）

日本イーライリリー株式会社(INDUSTRY)